|
|
|
Volumn 2, Issue 6, 2001, Pages 835-838
|
|
Overview: Gene-directed enzyme prodrug therapy (GDEPT) - Recognizing the present limitations of gene therapy for the treatment of cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE;
ACTINOMYCIN DERIVATIVE;
ALKYLATING AGENT;
ANTINEOPLASTIC AGENT;
DRUG METABOLITE;
ENZYME;
FLUCYTOSINE;
FLUOROURACIL;
GANCICLOVIR;
MITOMYCIN C;
NITROFURAL;
ONYX 015;
PRODRUG;
TALLIMUSTINE;
UNCLASSIFIED DRUG;
VIRUS VECTOR;
ACCURACY;
ANIMAL CELL;
BIOENGINEERING;
BRASSICA;
CANCER;
CANCER CELL;
CANCER IMMUNOTHERAPY;
CELL KILLING;
CLINICAL TRIAL;
CYTOTOXICITY;
DRUG ACTIVATION;
DRUG MECHANISM;
DRUG METABOLISM;
EDITORIAL;
GENE DIRECTED ENZYME PRODRUG THERAPY;
GENE EXPRESSION;
GENE TARGETING;
GENE THERAPY;
GENETIC STABILITY;
GENETIC TRANSDUCTION;
HERPES SIMPLEX VIRUS;
HUMAN;
TARGET CELL;
TUMOR SUPPRESSOR GENE;
TUMOR VOLUME;
TUMOR XENOGRAFT;
ANIMAL;
NEOPLASM;
REVIEW;
ANIMALS;
ANTINEOPLASTIC AGENTS;
GENE THERAPY;
HUMANS;
NEOPLASMS;
PRODRUGS;
|
|
EID: 0034795473
PISSN: 09678298
EISSN: None
Source Type: Journal
DOI: None Document Type: Editorial |
|
Times cited : (6)
|
|
References (0)
|
